Biomarkers: Technological and Commercial Outlook 2013-2023

PR Newswire

NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers: Technological and Commercial Outlook 2013-2023

http://www.reportlinker.com/p0578545/Biomarkers-Technological-and-Commercial-Outlook-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Report Details

Biomarkers - how to find R&D trends and potential sales

What's the outlook for biomarkers? Visiongain's updated report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.

That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. See what's happening for those technologies, finding how you can gain.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts 2013-2023 and other analyses show you commercial prospects

Besides revenue forecasting, our work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 65 tables, 60 charts, and two interviews.

Is your searching for data on biomarkers a challenging task? Now make it easier. You can stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

Our new study lets you investigate the most promising and lucrative parts of that field - assess technologies and their applications. You hear what's happening and see where the money lies. Try our new report, then, getting a feel for that industry's potential.

The following sections show how you benefit from our investigation.

Prospects for the world biomarkers market and its submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of 11 biomarker submarkets to 2023, starting with main divisions:• Discovery• Diagnostics• Services.

You see, too, world revenues to 2023 divided into technological disciplines:

• Genomics

• Proteomics

• Bioinformatics

• Other applications.

You also find world revenue predictions to 2023 by therapeutic field:• Cancers• Cardiovascular diseases• CNS disorders• Other illnesses.

How will those markets for biomarkers expand? Which applications will generate most money? You investigate that industry, finding the most promising places for investments and sales.

The study also breaks its overall forecast into geographical regions.

National markets - what outlooks for biomarker demand?

Worldwide progress in pharmaceuticals and diagnostics expand use of biomarkers. Hear about the best revenue prospects for those medical tools.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

• US

• Japan

• Germany, France, UK, Italy, and Spain (EU5)

• Brazil, Russia, India, and China (BRIC).

There you discover countries with highest revenues and potential sales growth. Our work explains. You assess that technology's future, seeing progress and finding what it means.

Developments and opportunities affecting biomarkers

Our report shows you issues and events affecting that industry and market from 2013, including these:• Biomarkers for efficacy and safety of drugs• Companion diagnostics and personalised medicines• Imaging biomarkers in clinical trials• Pharmacogenomics, proteomics, and metabolomics.

That study discusses other aspects of the technology too, including these:

• Funding for biomarker discovery and research

• Validation of biomarkers in oncology

• Mergers and acquisitions (M&A)

• Alliances, partnerships, collaborations, and licensing

• Interest from pharma companies, inc. Pfizer, Novartis, Merck, Sanofi, and Roche.

There you explore political, economic, social, and technological questions, assessing outlooks for business. See, then, what restrains and what helps the biomarkers industry.

You investigate R&D too, finding possibilities for technological and commercial advances. See there what the future holds.

Companies and 2018 market value

What happens next? Our report predicts the world market for biomarker systems will reach $29.25bn in 2018 - with high growth - and expand further to 2023. Find how high revenues can go.

Our work also shows you what technologies and organisations hold greatest potential. See profiles of 25 companies. First you examine contract service providers (CROs), including these:• Quintiles• Covance• Parexel• Charles River Laboratories• ICON• WuXi AppTec.

Next you assess technology providers, including these companies:

• Affymetrix

• Agilent

• QIAGEN

• Life Technologies

• Thermo Fisher Scientific.

Then, for diagnostic testing systems, you examine developers and producers including these:• Quest Diagnostics• Myriad Genetics• Genomic Health• Critical Diagnostics• MDxHealth.

There you analyse participants' results, capabilities, and outlooks. You find 210 organisations mentioned. You also read two interviews with leaders in the industry. Discover what authorities think, say, and do, helping you stay ahead.

Information found nowhere else

Biomarkers: Technological and Commercial Outlook 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.

With that report you are less likely to fall behind in knowledge or miss sales opportunity. See how you could benefit your research, analysis, and decisions. Also find how you can save time and get recognition for insight.

Biomarkers for healthcare - assess potentials now, seeing what you can gain

Our new report is for everyone investigating biomarker technologies. There discover revenue forecasts to 2023 at overall world market, submarket, and national level. Find discussions too. Avoid missing out then - please order the report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary1.1 Biomarkers: World Market Overview

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

1.4 Market Definition, 2013

2. An Introduction to Biomarkers

2.1 Definition of a Biomarker2.1.1 A Brief History of Biomarkers2.1.2 The Importance of Biomarkers2.2 Biomarker Discovery and Validation2.3 Uses of Biomarkers2.3.1 Assessing Drug Efficacy2.3.2 Assessing Drug Safety2.3.3 Companion Diagnostics2.3.3.1 CLIA vs. FDA Approval2.3.4 Therapeutic Importance of Biomarkers2.3.5 Imaging Biomarkers2.3.5.1 Imaging Biomarkers in Clinical Trials2.4 Biomarkers and Personalised Medicine2.5 Biomarker Discovery2.5.1 Genomics2.5.1.1 Pharmacogenomics2.5.2 Proteomics2.5.3 Metabolomics

3. The World Biomarkers Market, 2013-2023

3.1 The World Biomarkers Market, 2012

3.1.1 The World Biomarkers Market by Sector, 2012

3.1.2 The World Biomarkers Market by Discipline, 2012

3.2 The World Biomarkers Market: Overall Revenue Forecast, 2013-2023

3.2.1 Lack of Investment and Reimbursement Issues May Restrain Market

3.3 The World Biomarker Discovery Submarket, 2012

3.3.1 The World Biomarker Discovery Submarket: Revenue Forecast 2013-2023

3.4 The World Biomarker Diagnostics Submarket, 2012

3.4.1 The World Biomarker Diagnostics Submarket: Revenue Forecast, 2013-2023

3.5 The World Biomarker Services Submarket, 2012

3.5.1 The World Biomarker Services Submarket: Revenue Forecast, 2013-2023

3.6 The World Biomarkers Market: Overall Revenue Forecast by Discipline, 2013-2023

3.6.1 The Genomics Submarket: Revenue Forecast, 2013-2023

3.6.1.1 Next Generation Sequencing to Drive Growth

3.6.1.2 Increased Focus on Genomic Research in China

3.6.1.3 Application in Cardiovascular Disease

3.6.2 The Proteomics Submarket: Revenue Forecast, 2013-2023

3.6.2.1 Advances in Detection Technology Will Drive Market

3.6.3 The Bioinformatics Submarket: Revenue Forecast, 2013-2023

3.6.3.1 Market to Gather Pace with New Tools and Software in Pipeline

3.7 Growth in Key Biomarker Disciplines, 2013-2023

4. Leading Indications for Biomarker Discovery and Development, 2013-2023

4.1 The World Biomarkers Market by Indication, 20124.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2013-20234.3 Cancer Biomarker Submarket, 20124.3.1 A Brief History of Cancer Biomarker Research4.3.2 The Current State of Cancer Biomarker Research4.3.2.1 Cancer Genome Atlas4.3.3 Many Cancer Diagnostics Are Reaching the Market4.3.4 Opportunities and Challenges for Cancer Biomarkers4.3.4.1 Prostate Cancer: The Search for Urine Biomarkers4.3.4.2 Lung Cancer: High Biomarker Owing to Disease Prevalence4.3.5 Cancer Biomarker Submarket: Revenue Forecast, 2013-20234.4 Cardiovascular Disease Biomarker Submarket, 20124.4.1 A Brief History of Cardiovascular Biomarker Research4.4.2 The Current State of Cardiovascular Disease Biomarker Research4.4.3 Cardiovascular Disease Diagnostics4.4.4 The Future of Cardiovascular Biomarker Research4.4.5 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2013-20234.5 CNS Diseases Biomarker Submarket, 20124.5.1 The Current State of CNS Disease Biomarker Research4.5.2 Biomarker-Based Diagnostics for CNS Diseases4.5.2.1 DiaGenic: Targeting Neurodegenerative Diseases4.5.3 Neuroimaging Biomarkers: Limitations in Sensitivity May Restrict Market4.5.4 CSF Biomarkers: Biochemical Composition of CSF Offers Potential4.5.5 Alzheimer's Disease: Beyond Amyloid Beta4.5.6 Multiple Sclerosis: Search for Disease Biomarker4.5.7 Parkinson's Disease: Effective Biomarker Yet to be Discovered4.5.7.1 Fluid-Based Biomarker Discovery4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2013-20234.6 Growth in Key Biomarker Indications, 2013-2023

5. Leading National Biomarker Markets, 2013-2023

5.1 The World Biomarkers Market: Regional Breakdown, 2012

5.2 The World Biomarkers Market: Regional Forecast, 2013-2023

5.3 Strong Base for Biomarker Research in US

5.3.1 The US Biomarker Market: Revenue Forecast, 2013-2023

5.4 Top 5 EU Biomarker Markets, 2012

5.4.1 Top 5 EU Biomarker Markets: Revenue Forecasts, 2013-2023

5.4.2 French Government Funds $17m Cancer Biomarker Effort

5.4.2.1 France: Biomarker Market Revenue Forecast, 2013-2023

5.4.3 Focus on Biomarkers Prompts Opening of New Centre in Germany

5.4.3.1 Germany: Biomarker Market Revenue Forecast, 2013-2023

5.4.4 UK: Increased Funding for Biomarker Research

5.4.4.1 The UK Biomarker Market: Revenue Forecast, 2013-2023

5.4.5 Healthcare Cuts Restricting Drug Development in Spain

5.4.5.1 Spain: Biomarker Market Revenue Forecast, 2013-2023

5.4.6 Italy: United Action to Increase Validation of Oncology Biomarkers

5.4.6.1 Italy: Biomarker Market Revenue Forecast, 2013-2023

5.5 Company Alliances and Partnerships Grow in Japan

5.5.1 Japan: Biomarker Market Revenue Forecast, 2013-2023

5.6 Expanding Economy Driving Biotechnology in China

5.6.1 Companies Entering the Chinese Market

5.6.2 LightArray Biotech

5.6.3 China: Biomarker Market Revenue Forecast, 2013-2023

5.7 Attractiveness of Drug Development Outsourcing in India

5.7.1 India: Biomarker Market Revenue Forecast, 2013-2023

5.8 Investment in Local Drug Development to Drive Russian Market

5.8.1 Russia: Biomarker Market Revenue Forecast, 2013-2023

5.9 Brazil: Diagnostic Cardiac Biomarkers Gains Interest

5.9.1 Brazil: Biomarker Market Revenue Forecast, 2013-2023

6. Biomarker Industry Trends, 2013-2023

6.1 Strengths and Weaknesses of the Biomarkers Market, 20126.2 Opportunities and Threats in the Biomarkers Market, 2013-20236.3 STEP Analysis of the World Biomarkers Market6.4 Social Factors6.4.1 Patient Stratification: Striving Towards Personalised Medicine6.4.2 Biomarker Hype May Not Always Lead to New Discoveries6.4.3 Growing Emphasis on Oncology for Companies6.5 Technological Factors6.5.1 Decreasing Size, Increasing Sensitivity6.5.1.1 ABT Molecular Imaging6.5.2 The Need for More-Efficient Data Storage6.6 Economic Factors6.6.1 Biomarkers: Cutting the Cost of Drug Development6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups6.6.3 Outsourcing Biomarker Discovery and Development6.7 Political Factors6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery6.7.2 Improving Regulatory Guidelines to Speed Development6.7.3 Concerns over Biomarker Patenting Hits Innovation6.8 Challenges in Developing Biomarkers6.9 Combining Drug and Diagnostic Development6.10 MicroRNA Biomarkers: A Prospective Target?6.11 Big Pharma and Biomarkers6.11.1 Pfizer: Loss of Patent Protection on Key Drug Prompts Search for New Biomarkers6.11.2 Novartis: Spotlight on Cancer Biomarkers6.11.3 Merck & Co.: Multi-Platform Applications for Company's Biomarkers6.11.4 Sanofi: Developing Cancer Companion Diagnostics6.11.5 Roche6.11.5.1 Roche Diagnostics6.11.5.2 Ventana Medical Systems6.11.5.3 Roche 454 Life Sciences6.11.6 GSK: Using Genomic Technologies to Discover Fibrosis Biomarkers6.11.7 AstraZeneca: Speciality Focus Through Dedicated In-House Biomarker Team6.11.8 Abbott Laboratories/Abbott Molecular: Licensing Agreements and Acquisitions

7. Leading Companies in the Biomarkers Market, 2013

7.1 Biomarker Service Providers

7.1.1 Global CROs and Biomarkers

7.1.1.1 Not All Global CROs Are Investing in Biomarkers

7.1.2 Quintiles: Leading Biomarker Developer with Strong Portfolio

7.1.3 Covance: Specialist Team Prompts Opening of New Biomarker: New Centre

7.1.4 Parexel: New Direction in Neuronal Biomarkers?

7.1.5 Charles River Laboratories: In Vitro Biomarker Platforms

7.1.6 ICON: Offering a Range of Biomarker Activities

7.1.7 WuXi AppTec: Agreement with QIAGEN Allows Shared Expertise

7.1.8 Caprion Proteomics: Specialising In Protein Biomarkers

7.1.9 Proteome Sciences: Sales Surge Due to Biomarker Licensing

7.1.10 Pacific Biomarkers: Penetrating the Indian Market

7.1.11 Oxford Gene Technology: Caner and Lupus Biomarkers in Pipeline

7.1.12 Worldwide Clinical Trials: Dedicated Laboratory in Place for Biomarker Services

7.2 Biomarker Technology Providers

7.2.1 Affymetrix: Innovative GeneChip Technology Provides Discovery Platform

7.2.1.1 QuantiGene

7.2.2 Agilent: Broad Range of Technological Capabilities

7.2.2.1 Agilent and Diagnostics

7.2.2.2 Growing Asian Markets: Focus on South Korea

7.2.3 AB SCIEX: Next Generation Mass Specs to be Launched

7.2.4 QIAGEN: Strong History in Acquisitions and Licensing Agreements

7.2.5 Life Technologies: Provider of Next Generation Sequencing Systems

7.2.6 Axela: Simplifying Biomarker Development

7.2.7 Thermo Fisher Scientific: BRAHMS Acquisition Leads to Further Licensing Agreements

7.2.7.1 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre

7.3 Biomarker Diagnostic Developers

7.3.1 Quest Diagnostics: Celera Acquisition Expands Company Offerings

7.3.2 Myriad Genetics: Focus on Diagnostic Tests for Genetic Cancer Biomarkers

7.3.2.1 Pipeline

7.3.2.2 Myriad RBM

7.3.3 Genomic Health: Building on the Oncotype Dx Brand

7.3.4 Critical Diagnostics: Detecting Markers for Cardiovascular Indications

7.3.5 BG Medicine: Testing for Cardiovascular Disease

7.3.6 Epigenomics: Discovering Novel Biomarkers Through Company Alliances

7.3.6.1 Diagnostic Product Portfolio

7.3.7 MDxHealth: Applying DNA Methylation Techniques in Biomarker Discovery

8. Opinions from Our Survey: Research Interviews

8.1 Dr Thomas Turi, Vice President, Science and Technology, Discovery and Translational Services, Covance8.1.1 Evolution of the Biomarker Services Market8.1.2 Covance Services and Market Competition8.1.3 The Importance of Company Collaborations and Future Prospects8.2 Dr John L Allinson, Vice President Biomarker Laboratory Services, ICON plc.8.2.1 Outlook of the Current Biomarker Market8.2.2 Staying Ahead of Competition8.2.3 Leading Disease Indications and Market Threats

9. Conclusions

9.1 State of the World Biomarkers Market in 2012

9.2 Growth in the World Biomarkers Market, 2013-2023

9.2.1 Dominance of Leading Western Markets

9.3 The Use of Biomarkers in Drug Discovery and Development

9.4 Demand for New Diagnostics

List of Tables

Table 1.1 Currency Exchange Rates

Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2012

Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2012

Table 2.3 Technologies and Platforms for Biomarker Research, 2012

Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2012

Table 3.2 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2012

Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2013-2023

Table 3.4 World Biomarkers Market: Market Shares (%) by Sector, 2012-2023

Table 3.5 Biomarker Discovery Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 3.7 Biomarker Services Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 3.8 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2013-2023

Table 3.9 Genomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2012

Table 3.11 Proteomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 3.12 Bioinformatics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 3.13 World Biomarker Market: Market Shares (%) by Discipline, 2012-2023

Table 4.1 World Biomarkers Market: Market Share (%) by Indication, 2012

Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Indication, 2013-2023

Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2012

Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2012

Table 4.5 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2012-2023

Table 4.7 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 4.8 World Biomarkers Market: Market Share (%) by Indication, 2012-2023

Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2012

Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2013-2023

Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2012-2023

Table 5.4 US Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.5 Top 5 EU Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2012

Table 5.6 Top Five EU Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2013-2023

Table 5.7 France: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.8 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.9 UK Biomarker Market: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.10 Spain: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.11 Italy: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.12 Japan: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.13 China: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.14 India: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.15 Russia: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 5.16 Brazil: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023

Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2013-2023

Table 6.2 World Biomarkers Market: Opportunities and Threats, 2013-2023

Table 6.3 World Biomarkers Market: STEP Analysis, 2013-2023

Table 6.4 US Cancer Deaths by Tumour Type, 2012

Table 6.5 Selected Cancer Therapies Approved With a Biomarker, 2011

Table 6.6 PSTC Biomarkers in Development, 2012

Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($bn, AGR %, CAGR %), 2002-2012

Table 6.8 IMI-Funded Biomarker Projects, 2009-2012

Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast ($bn, AGR %, CAGR %), 2012, 2018 & 2023

Table 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012

Table 7.2 Proteome Sciences: Revenue, 2012-2012

Table 7.3 Affymetrix: Revenue by Division, 2010-2012

Table 7.4 Myriad Genetics: Biomarker Product Portfolio, 2012

Table 7.5 Myriad Genetics: Revenue by Product, 2012

Table 7.6 Myriad Genetics: Diagnostic Pipeline, 2012

Table 7.7 Genomic Health: Revenue by Division, 2010-2012

Table 7.8 BG Medicine: Revenue by Division, 2010-2012

Table 7.9 Epigenomics: Revenue and Market Shares by Sector, 2011 & 2012

Table 7.10 MDxHealth: Pipeline, 2012

Table 7.11 MDxHealth: Revenue by Source, 2010-2012

Table 9.1 World Biomarkers Market: Revenues ($bn, CAGR %) by Sector, 2012, 2018 and 2023

Table 9.2 World Biomarkers Market: Revenues ($bn, CAGR %) by Discipline, 2012, 2018 and 2023

Table 9.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease, 2012, 2018 and 2023

Table 9.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Country, 2012, 2018 and 2023

List of Figures

Figure 2.1 Definitions of a Biomarker, 2013

Figure 2.2 The Biomarker Discovery and Validation Process, 2013

Figure 3.1 World Biomarkers Market: Market Shares (%) by Sector, 2012

Figure 3.2 World Biomarkers Market: Market Shares (%) by Discipline, 2012

Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2013-2023

Figure 3.4 World Biomarkers Market: Overall Market Forecast ($bn), 2013-2023

Figure 3.5 World Biomarkers Market: Market Shares (%) by Sector, 2018

Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2023

Figure 3.7 Biomarker Discovery Submarket: Drivers and Restraints, 2013-2023

Figure 3.8 Biomarker Discovery Submarket: Revenue Forecast ($bn), 2013-2023

Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast ($bn), 2013-2023

Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2013-2023

Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2013-2023

Figure 3.12 Biomarker Services Submarket: Revenue Forecast ($bn), 2013-2023

Figure 3.13 Genomics Submarket: Revenue Forecast ($bn), 2013-2023

Figure 3.14 Genomics Submarket: Drivers and Restraints, 2013-2023

Figure 3.15 Proteomics Submarket: Drivers and Restraints, 2013-2023

Figure 3.16 Proteomics Submarket: Revenue Forecast ($bn), 2013-2023

Figure 3.17 Bioinformatics Submarket: Revenue Forecast ($bn), 2013-2023

Figure 3.18 Bioinformatics Submarket: Drivers and Restraints, 2013-2023

Figure 3.19 World Biomarkers Market: Market Shares (%) by Discipline, 2018

Figure 3.20 World Biomarkers Market: Market Shares (%) by Discipline, 2023

Figure 4.1 World Biomarkers Market: Market Share (%) by Indication, 2012

Figure 4.2 Cancer Submarket: Revenue Forecast ($bn), 2013-2023

Figure 4.3 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2013-2023

Figure 4.4 CNS Diseases Submarket: Revenue Forecast ($bn), 2013-2023

Figure 4.5 World Biomarkers Market: Market Share (%) by Indication, 2018

Figure 4.6 World Biomarkers Market: Market Shares (%) by Indication, 2023

Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2012

Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2018

Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2023

Figure 5.4 US Biomarkers Market: Revenue Forecast ($bn), 2013-2023

Figure 5.5 Top 5 EU Biomarker Markets: Market Share (%) by Country, 2012

Figure 5.6 Top Five EU Biomarker Markets: Revenue Forecasts ($bn), 2013-2023

Figure 5.7 France: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.8 Germany: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.9 UK Biomarker Market: Revenue Forecast ($bn), 2013-2023

Figure 5.10 Spain: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.11 Italy: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.12 Japan Biomarker Market: Revenue Forecast ($bn), 2013-2023

Figure 5.13 China: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.14 India: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.15 Russia: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 5.16 Brazil: Biomarker Market Revenue Forecast ($bn), 2013-2023

Figure 6.1 US Cancer Deaths: Market Share (%) by Tumour Type, 2012

Figure 6.2 Average Cost of Sequencing the Human Genome, 2002-2007

Figure 6.3 Average Cost of Sequencing the Human Genome, 2007-2012

Figure 6.4 Drug Discovery Outsourcing: Overall Market and Subsector Revenues ($bn), 2012, 2018 & 2023

Figure 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012

Figure 7.2 Proteome Sciences: Revenue, 2011-2012

Figure 7.3 Affymetrix: Revenue by Division, 2010-2012

Figure 7.4 Myriad Genetics: Market Shares by Product, 2012

Figure 7.5 Genomic Health: Product Revenue, 2010-2012

Figure 7.6 BG Medicine: Product Revenue, 2010-2012

Figure 7.7 Epigenomics: Revenue by Half-Year, 2010-2011

Figure 7.8 MDxHealth: Revenue by Source, 2010-2012

Figure 9.1 World Biomarkers Market: Revenues ($bn) by Sector, 2012, 2018 and 2023

Figure 9.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2012, 2018 and 2023

Figure 9.3 World Biomarkers Market: Revenues ($bn) by Disease, 2012, 2018 and 2023

Figure 9.4 World Biomarkers Market: Revenues ($bn) by Country, 2012, 2018 and 2023

Companies Listed

454 Life Sciences (a subsidiary of Roche)

AB SCIEX (a subsidiary of Danaher)

Abbott Laboratories

Abbott Molecular

Abcodia

ABT Molecular Imaging

ACS Biomarker

Advanced Cell Diagnostics (ACD)

Advion Bioanalytical Labs (part of Quintiles)

Affymetrix

Agendia

Agilent

Alacris Theranostics

Alere

Amarantus BioSciences

American College of Cardiology Foundation (ACCF)

American Heart Association (AHA)

Applied Biosystems (part of Life Technologies)

Arctic Partners

ARIAD Pharmaceuticals

Ariana Pharma

Arizona State University

Arrayit

ARUP Laboratories

Association for Molecular Pathology (AMP) [US]

AstraZeneca

Athena Diagnostics (a subsidiary of Quest Diagnostics)

Atherotech Diagnostics Lab

Aushon Biosystems

Axela

Bayer

Belfer Institute for Applied Cancer Science [US]

Berkeley HeartLab (a subsidiary of Quest Diagnostics)

BG Medicine

BGI (formerly Beijing Genomics Institute)

Biofortis

Biosoft

BRAHMS (part of Thermo Fisher Scientific)

Brigham and Women's Hospital

Bristol-Myers Squibb

British Heart Foundation [UK]

Broad Institute [US]

Cancer Research Technology

Cancer Research UK

Caprion Proteomics

Celera (part of Quest Diagnostics)

Celgene

Cell Signaling Technology

Celldex Therapeutics

Centers for Medicare and Medicaid Services (CMS) [US]

Cephalon (part of Teva)

Charles River Laboratories

Chinese State Food and Drug Administration (SFDA)

Chronix Biomedical

Chugai Pharmaceutical

Ciphergen Biosystems

Clarient

Cleveland HeartLab

Clinigene International

Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]

Comprehensive Biomarker Center (formerly Febit)

Covance

Critical Diagnostics

Critical Path Institute (C-Path) [US]

CTI Biotech

Dako (now part of Agilent)

Dana-Farber Cancer Institute [US]

Danaher

DaVita Labs

DiaGenic

Durin Technologies

DxS (now part of QIAGEN)

EKO Diagnostic

Eli Lilly

Epigenomics

Epistem

EQT

ETH Zurich

European Commission

European Federation of Pharmaceutical Industries and Associations (EFPIA)

European Medicines Agency (EMA)

European Stroke Research Network for Hypothermia (Euro-HYP)

Evotec

Exact Sciences

Exiqon

Exonhit

Ezose Sciences (part of Shionogi)

Food and Drug Administration (FDA) [US]

Foundation Medicine

Fujirebio Diagnostics

GE Healthcare

Genetic Technologies

Geneva Bioinformatics (GeneBio)

Genomic Health

GenWay Biotech

Great Point Partners

GSK

Health Diagnostic Laboratory

HealthLinx

Helicos BioSciences

Hewlett-Packard

Hirosaki University

HTG Molecular Diagnostics

Human Proteome Organisation (HUPO)

ICON

Insight Genetics

Integrated Diagnostics

International Cancer Genome Consortium (ICGC)

Ipsen

Ipsogen (a subsidiary of QIAGEN)

Isogen Life Science

Johnson & Johnson (J&J)

KU Leuven (University of Leuven)

LabCorp

Les entreprises du médicament (LEEM) [France]

Life Technologies

LightArray Biotech

M2Gen

Malmö University

Massachusetts General Hospital

Max Planck Institute for Molecular Genetics [Germany]

Mayo Clinic [US]

Mayo Collaborative Services

MDxHealth

Medical Research Council [UK]

Memorial Sloan-Kettering Cancer Center [US]

Merck & Co.

Merck KGaA

Metabolon

Michael J Fox Foundation

Myriad Genetics

Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)

National Academy of Sciences (NAS) [US]

National Cancer Institute (NCI) [US]

National Health Service (NHS) [UK]

National Human Genome Research Institute (NHGRI) [US]

National Institute for Health and Clinical Excellence (NICE) [UK]

National Institute of Allergy and Infectious Diseases (NIAID) [US]

National Institute on Aging (NIA) [US]

National Jewish Health [US]

Nephromics

Newcastle University [UK]

Novartis

Novartis Molecular Diagnostics (part of Novartis)

NovioGendix

Oncoimmune

Oncomedics

OpGen

OPKO Health

Orion Genomics

Oslo University Hospital

Oxford Cancer Biomarkers

Oxford Gene Technology (OGT)

Pacific Biomarkers

Pacific Biosciences

Panomics (now part of Affymetrix)

Parexel

Pathwork Diagnostics

Personal Genome Diagnostics

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]

Pierre Fabre

PLUS Diagnostics

Power3 Medical Products

PPD

Predictive Biosciences

Predictive Safety Testing Consortium (PSTC) [US]

Prometheus Laboratories

Proteome Sciences

QIAGEN

QLIDA Diagnostics

Quanterix

Quanticel Pharmaceuticals

Quest Diagnostics

Quintiles

Randox Laboratories

Roche

SABiosciences (now part of QIAGEN)

Sandor Proteomic

Sanofi

Santaris Pharma

Servier

Shanghai Jiao Tong University

Shionogi

Siemens

SMA Foundation [US]

Stanford University

State Food and Drug Administration (SFDA) [China]

Stemina Biomarker Discovery

Sysmex

Technion-Israel Institute of Technology

Technology Strategy Board (TSB) [UK]

Teva Pharmaceutical Industries

Thallion Pharmaceuticals

The Biomarkers Consortium

Thermo Fisher Scientific

Transgene

Trans-Hit Biomarkers

Tufts Center for the Study of Drug Development

University of Alabama

University of Medicine and Dentistry of New Jersey (UMDNJ)

University of Oslo

University of Turku

University of Washington

Ventana Medical Systems

Vertex Pharmaceuticals

WaferGen

Warnex

Wellcome Trust Sanger Institute [UK]

World Health Organization (WHO)

WuXi AppTec

Xcovery

To order this report:Genomics Industry: Biomarkers: Technological and Commercial Outlook 2013-2023

__________________________

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

View Comments